Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hiPSC-derived oligodendrocyte progenitor cells (Trailhead Biosystems)
- Development stage
- Preclinical
- Lead developer
- Trailhead Biosystems
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intranasal, Direct Injection, Intrathecal
01
Overview
Trailhead Biosystems' hiPSC-derived oligodendrocyte progenitor cells (OPCs) are an induced pluripotent stem cell (iPSC)-derived cell therapy product designed for the treatment of neurological and demyelinating diseases. Developed using the company's proprietary High-Dimensional Design of Experiments (HD-DoE) platform, these cells are engineered to differentiate into mature, myelinating oligodendrocytes upon transplantation. The primary mechanism of action is the restoration of the myelin sheath around damaged axons (remyelination) and the provision of trophic support to neurons, which aims to restore nerve conduction and prevent further neurodegeneration in conditions such as multiple sclerosis and leukodystrophies.
- Other names
- Oligodendrocyte ProgenitorshiPSC-derived OPCsTrailhead Biosystems oligodendrocyte lineage cells
Beyond the preview
Go deeper on hiPSC-derived oligodendrocyte progenitor cells (Trailhead Biosystems).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hiPSC-derived oligodendrocyte progenitor cells (Trailhead Biosystems).